SynthesisGenetic testing and molecular biomarkers2013
Association between TGF-β1 polymorphisms and hepatocellular carcinoma risk: a meta-analysis.
Synthesis in Genetic testing and molecular biomarkers, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 3 syntheses or guidelines pooled it, 14 citations in OpenAlex.
- Pooled it
- High TGF-β1 expression predicts poor disease prognosis in hepatocellular carcinoma patients.Oncotarget · 2017Pooled it
- Pooled it
- A pilot study on some critical immune elements in HBV infection: evidence of Alpha-1 Antitrypsin as an immunological biomarker.Gastroenterology and hepatology from bed to bench · 2022Article
- Genetic dominance of transforming growth factor-β1 polymorphisms in chronic liver disease.Frontiers in immunology · 2022Article
- TGF-Β1 & PNPLA3 Genetic Variants and the Risk of Hepatic Fibrosis and HCC in Egyptian Patients with HCV-Related Liver Cirrhosis.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- Association between host TNF-α, TGF-β1, p53 polymorphisms, HBV X gene mutation, HBV viral load and the progression of HBV-associated chronic liver disease in Indonesian patients.Biomedical reports · 2019Article
- Relationship between HLA-DRB1 allele polymorphisms and familial aggregations of hepatocellular carcinoma.Current oncology (Toronto, Ont.) · 2016Article
- TGF-β1-509C/T polymorphism and the risk of ESCC in a Chinese Han population.International journal of clinical and experimental medicine · 2015Article
- TGF-β1 C-509T and T869C polymorphisms and cancer risk: a meta analysis.International journal of clinical and experimental medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAssociations between transforming growth factor (TGF)-β1 polymorphisms and hepatocellular carcinoma (HCC) risk remained controversial. Therefore, we performed this meta-analysis to investigate these associations.
methodsWe searched Pubmed, EMBASE, Chinese National Knowledge Infrastructure (CNKI), and Wanfang databases for studies before March 2013. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to calculate the strength of association.
resultsA total of 14 studies were included in this meta-analysis. TGF-β1 +869C/T polymorphism was significantly associated with HCC risk (OR=1.74, 95% CI: 1.22-2.47, p=0.002). In addition, a significant association between -509C/T polymorphism and HCC risk was observed (OR=1.40, 95% CI: 1.15-1.70, p=0.0007). Furthermore, significant associations between these polymorphisms and HCC risk were found in Asians and population-based studies.
conclusionsOur meta-analysis suggested that the TGF-β1 +869C/T and -509C/T polymorphisms may be risk factors for developing HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.